Citigroup’s Alnylam Pharmaceuticals ALNY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.97M | Sell |
12,000
-18,000
| -60% | -$6.13M | ﹤0.01% | 2138 |
|
|
2025
Q4 | $11.9M | Hold |
30,000
| – | – | 0.01% | 1407 |
|
|
2025
Q3 | $13.7M | Buy |
+30,000
| New | +$12.2M | 0.01% | 1288 |
|
|
2025
Q1 | – | Sell |
-30,000
| Closed | -$7.06M | – | 5546 |
|
|
2024
Q4 | $7.06M | Sell |
30,000
-10,600
| -26% | -$2.79M | ﹤0.01% | 1652 |
|
|
2024
Q3 | $11.2M | Sell |
40,600
-50,700
| -56% | -$13.2M | 0.01% | 1277 |
|
|
2024
Q2 | $22.2M | Buy |
91,300
+87,300
| +2,183% | +$13.8M | 0.01% | 832 |
|
|
2024
Q1 | $598K | Sell |
4,000
-21,000
| -84% | -$3.5M | ﹤0.01% | 3445 |
|
|
2023
Q4 | $4.79M | Buy |
25,000
+5,100
| +26% | +$869K | ﹤0.01% | 1625 |
|
|
2023
Q3 | $3.52M | Buy |
+19,900
| New | +$3.8M | ﹤0.01% | 1621 |
|
|
2023
Q1 | – | Sell |
-77,000
| Closed | -$18.3M | – | 5465 |
|
|
2022
Q4 | $18.3M | Buy |
77,000
+26,500
| +52% | +$5.65M | 0.01% | 842 |
|
|
2022
Q3 | $10.1M | Buy |
50,500
+45,500
| +910% | +$8.68M | 0.01% | 1135 |
|
|
2022
Q2 | $729K | Buy |
+5,000
| New | +$709K | ﹤0.01% | 2936 |
|
|
2021
Q1 | – | Sell |
-21,200
| Closed | -$2.75M | – | 6202 |
|
|
2020
Q4 | $2.75M | Sell |
21,200
-10,600
| -33% | -$1.42M | ﹤0.01% | 2556 |
|
|
2020
Q3 | $4.63M | Buy |
31,800
+2,100
| +7% | +$298K | ﹤0.01% | 1941 |
|
|
2020
Q2 | $4.4M | Sell |
29,700
-13,200
| -31% | -$1.78M | ﹤0.01% | 1976 |
|
|
2020
Q1 | $4.67M | Buy |
42,900
+500
| +1% | +$57.7K | ﹤0.01% | 1736 |
|
|
2019
Q4 | $4.88M | Buy |
42,400
+1,100
| +3% | +$110K | ﹤0.01% | 2048 |
|
|
2019
Q3 | $3.32M | Buy |
41,300
+14,600
| +55% | +$1.16M | ﹤0.01% | 2322 |
|
|
2019
Q2 | $1.94M | Buy |
26,700
+7,500
| +39% | +$575K | ﹤0.01% | 2890 |
|
|
2019
Q1 | $1.79M | Buy |
19,200
+1,100
| +6% | +$92K | ﹤0.01% | 2759 |
|
|
2018
Q4 | $1.32M | Sell |
18,100
-11,800
| -39% | -$908K | ﹤0.01% | 3112 |
|
|
2018
Q3 | $2.62M | Buy |
29,900
+12,400
| +71% | +$1.25M | ﹤0.01% | 2490 |
|
|
2018
Q2 | $1.72M | Sell |
17,500
-7,900
| -31% | -$784K | ﹤0.01% | 2813 |
|
|
2018
Q1 | $3.02M | Sell |
25,400
-32,900
| -56% | -$4.24M | ﹤0.01% | 2235 |
|
|
2017
Q4 | $7.41M | Buy |
58,300
+6,400
| +12% | +$804K | 0.01% | 1495 |
|
|
2017
Q3 | $6.1M | Sell |
51,900
-5,200
| -9% | -$444K | 0.01% | 1582 |
|
|
2017
Q2 | $4.55M | Buy |
57,100
+4,300
| +8% | +$275K | ﹤0.01% | 1771 |
|
|
2017
Q1 | $2.71M | Buy |
52,800
+700
| +1% | +$32.4K | ﹤0.01% | 2181 |
|
|
2016
Q4 | $1.95M | Buy |
52,100
+11,000
| +27% | +$461K | ﹤0.01% | 2980 |
|
|
2016
Q3 | $2.79M | Buy |
41,100
+5,200
| +14% | +$367K | ﹤0.01% | 2211 |
|
|
2016
Q2 | $1.99M | Buy |
35,900
+6,900
| +24% | +$435K | ﹤0.01% | 2344 |
|
|
2016
Q1 | $1.82M | Buy |
29,000
+9,500
| +49% | +$632K | ﹤0.01% | 2611 |
|
|
2015
Q4 | $1.84M | Buy |
19,500
+8,200
| +73% | +$760K | ﹤0.01% | 2547 |
|
|
2015
Q3 | $908K | Buy |
11,300
+2,600
| +30% | +$289K | ﹤0.01% | 3181 |
|
|
2015
Q2 | $1.04M | Buy |
8,700
+8,500
| +4,250% | +$1.02M | ﹤0.01% | 3125 |
|
|
2015
Q1 | $21K | Buy |
+200
| New | +$20.3K | ﹤0.01% | 6068 |
|
Other funds holding ALNY
VPM
VCM
Citigroup's ALNY Position: Q1 2026 in Review
Citigroup increased its Alnylam Pharmaceuticals (ALNY) stake by 53% in Q1 2026, buying an estimated $30.9M and bringing the position to 263,375 shares worth $87.1M. The position accounts for 0.04% of the portfolio, ranked #449.
Citigroup first reported a position in ALNY in Q2 2013 and has held it in 52 quarters since. The position peaked at $97.6M in Q2 2024. 787 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.
- Citigroup held 263,375 shares of Alnylam Pharmaceuticals worth $87.1M as of Q1 2026.
- Citigroup bought 90,813 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $30.9M.
- Alnylam Pharmaceuticals made up 0.04% of Citigroup's portfolio in Q1 2026, its #449 holding.
- Citigroup first reported a position in Alnylam Pharmaceuticals in Q2 2013 and has held it in 52 quarters since.
- Citigroup's Alnylam Pharmaceuticals position peaked at $97.6M in Q2 2024.
- 787 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.
Based on Citigroup's 13F filing for Q1 2026, filed 11 May 2026.